Drug intelligence / Profile preview

epimestrol

Development stage: Discontinued
Lead developer: Organon
Modality: Small Molecules
Administration: Oral

Overview

Epimestrol is a synthetic, steroidal estrogen and an estrogen ether that acts as a prodrug of 17-epiestriol. It is classified as a weak estrogen and has been used primarily in the treatment of female infertility due to anovulation and amenorrhea, often as part of ovulation induction protocols in combination with gonadotropin-releasing hormone. Epimestrol exerts its effects by modulating the secretion of gonadotropins (LH, FSH) and prolactin at the hypothalamic-pituitary axis, leading to increased levels of these hormones during therapy. Its mechanism involves activation of estrogen receptors after conversion to its active form[1][4][6][7].

Brand names: AleneStimovul
Other names: 3-methoxy-17-epiestriol3-methoxyestriolepimestrolum

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on epimestrol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epimestrol.

Explore the full profile